AlloStem Shows Potential in Reducing Insulin Dependency for Late-Stage Type 2 Diabetes
A pilot study of Creative Medical Technology’s AlloStem (CELZ-201) reported an 80% efficacy rate in reducing insulin dependency and stabilizing hemoglobin A1c levels in late-stage type 2 diabetes, with no serious safety events observed.
